In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo.
MT
Dr. Mary-Ellen Taplin
Medical Oncology · Genitourinary OncologyDana-Farber Cancer Institutemaryellen